Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Antares Therapeutics, a spin-off from Scorpion Therapeutics, has secured $177 million in Series A financing from notable investors including Omega Funds and Atlas Venture to advance its cancer drug programs.
Amount Raised
$177 Million
Round Type
Series A
Investors
Description
Antares Therapeutics has launched with $177 million in Series A financing following a successful deal with Eli Lilly. The startup aims to further develop small molecule drugs initially worked on at Scorpion. Investors include previous backers Omega Funds and Atlas Venture. CEO Adam Friedman highlights the company's focus on addressing serious diseases through innovative drug discoveries.
Fundz sees it the moment Antares Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAntares Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.